Literature DB >> 9239396

Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis.

R Bertoni1, J Sidney, P Fowler, R W Chesnut, F V Chisari, A Sette.   

Abstract

The present study was designed to determine if highly conserved hepatitis B virus (HBV)-derived peptides that bind multiple HLA class I alleles with high affinity are recognized as cytotoxic T lymphocyte (CTL) epitopes in acutely infected patients. Peripheral blood mononuclear cells from 67 patients with acute hepatitis B, and 12 patients convalescent from acute hepatitis B, were stimulated with three panels of peptides, each of which bind with high affinity to several class I alleles from the HLA-A2-, HLA-A3-, or HLA-B7-supertypes. In these patients, 8 of the 19 peptides tested were found to represent CTL epitopes recognized by two or more alleles in each supertype. Two sets of nested peptides were recognized in the context of alleles with completely unrelated peptide binding specificities. Finally, promiscuous recognition by the same CTL of a given peptide presented by target cells expressing different A2 subtypes was also commonly observed. In conclusion, several HBV-specific CTL epitopes, recognized by acutely infected or convalescent patients in the context of a wide range of HLA alleles have been identified. These results demonstrate the functional relevance of the supertype grouping of HLA class I molecules in a human viral disease setting. Furthermore, they represent a significant advance in the development of a totally synthetic vaccine to terminate chronic HBV infection and support the feasibility of a systematic approach to development of similar vaccines for prevention and treatment of other chronic viral infections.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9239396      PMCID: PMC508216          DOI: 10.1172/JCI119559

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

2.  Truncation analysis of several DR binding epitopes.

Authors:  D O'Sullivan; J Sidney; M F Del Guercio; S M Colón; A Sette
Journal:  J Immunol       Date:  1991-02-15       Impact factor: 5.422

3.  Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition.

Authors:  J I Krieger; R W Karr; H M Grey; W Y Yu; D O'Sullivan; L Batovsky; Z L Zheng; S M Colón; F C Gaeta; J Sidney
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

4.  HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.

Authors:  A Bertoletti; C Ferrari; F Fiaccadori; A Penna; R Margolskee; H J Schlicht; P Fowler; S Guilhot; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types.

Authors:  J A Berzofsky; C D Pendleton; M Clerici; J Ahlers; D R Lucey; S D Putney; G M Shearer
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.

Authors:  C Ferrari; A Bertoletti; A Penna; A Cavalli; A Valli; G Missale; M Pilli; P Fowler; T Giuberti; F V Chisari
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

7.  Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection.

Authors:  B Rehermann; K M Chang; J G McHutchison; R Kokka; M Houghton; F V Chisari
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

8.  The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

Authors:  B Rehermann; C Ferrari; C Pasquinelli; F V Chisari
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

9.  Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.

Authors:  J Molldrem; S Dermime; K Parker; Y Z Jiang; D Mavroudis; N Hensel; P Fukushima; A J Barrett
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

10.  Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex.

Authors:  A Vitiello; D Marchesini; J Furze; L A Sherman; R W Chesnut
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  42 in total

1.  Parallel decline of CD8+CD38+ lymphocytes and viremia in treated hepatitis B patients.

Authors:  Wei Cao; Zhi-Feng Qiu; Tai-Sheng Li
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

Review 2.  Structural and functional distinctiveness of HLA-A2 allelic variants.

Authors:  Kenneth Yuanxiang Chen; Jingxian Liu; Ee Chee Ren
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires.

Authors:  John Sidney; Scott Southwood; Alessandro Sette
Journal:  Immunogenetics       Date:  2005-07-08       Impact factor: 2.846

4.  Identification and functional perspective of a novel HLA-A allele: A*0279.

Authors:  Fangfang Liu; Shan Wang; Yingjiang Ye; Huagang Zhang; Yu Zhang; Weifeng Chen
Journal:  Immunogenetics       Date:  2006-04-01       Impact factor: 2.846

5.  Detailed characterization of the peptide binding specificity of five common Patr class I MHC molecules.

Authors:  John Sidney; Shinichi Asabe; Bjoern Peters; Kelly-Anne Purton; Josan Chung; Timothy J Pencille; Robert Purcell; Christopher M Walker; Francis V Chisari; Alessandro Sette
Journal:  Immunogenetics       Date:  2006-06-22       Impact factor: 2.846

6.  An asymmetric model of heterozygote advantage at major histocompatibility complex genes: degenerate pathogen recognition and intersection advantage.

Authors:  Rick J Stoffels; Hamish G Spencer
Journal:  Genetics       Date:  2008-02-03       Impact factor: 4.562

7.  Extensive HLA class I allele promiscuity among viral CTL epitopes.

Authors:  Nicole Frahm; Karina Yusim; Todd J Suscovich; Sharon Adams; John Sidney; Peter Hraber; Hannah S Hewitt; Caitlyn H Linde; Daniel G Kavanagh; Tonia Woodberry; Leah M Henry; Kellie Faircloth; Jennifer Listgarten; Carl Kadie; Nebojsa Jojic; Kaori Sango; Nancy V Brown; Eunice Pae; M Tauheed Zaman; Florian Bihl; Ashok Khatri; Mina John; Simon Mallal; Francesco M Marincola; Bruce D Walker; Alessandro Sette; David Heckerman; Bette T Korber; Christian Brander
Journal:  Eur J Immunol       Date:  2007-09       Impact factor: 5.532

8.  CD8+ T-Cell Response-Associated Evolution of Hepatitis B Virus Core Protein and Disease Progress.

Authors:  George F Gao; Jingmin Zhao; Yu Zhang; Yan Wu; Mengmeng Deng; Dongping Xu; Xiaodong Li; Zhihui Xu; Jun Hu; Han Zhang; Kefang Liu; Yingze Zhao; Feng Gao; Shengli Bi; William J Liu; Songdong Meng
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

9.  Redundancy and Complementarity between ERAP1 and ERAP2 Revealed by their Effects on the Behcet's Disease-associated HLA-B*51 Peptidome.

Authors:  Pablo Guasp; Elena Lorente; Adrian Martín-Esteban; Eilon Barnea; Paolo Romania; Doriana Fruci; JonasJ W Kuiper; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2019-05-15       Impact factor: 5.911

10.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.